What Is Acute Lmphocytic Leukemia?

This content has been reviewed and approved by

Hagop M. Kantarjian, MD
Chairman & Professor, Leukemia Department
MD Anderson Cancer Center
University of Texas
 

Leukemia is cancer of the blood cells, usually the white blood cells. Acute lymphocytic leukemia (ALL) occurs when bone marrow and the lymph system produce too many lymphocytes. A lymphocyte is a type of white blood cell that fights infection by making antibodies that attack harmful organisms.

About 5,330 people in the United States will be diagnosed with ALL in 2010, according to the American Cancer Society (ACS). Although ALL is the most common leukemia in children, approximately one-third of cases occur in adults.

A person with ALL has immature lymphocytes that cannot function properly. They crowd out other blood cells and may collect in blood, bone marrow, and lymph tissue. People with ALL have difficulty in fighting infection. They also have a low platelet count and may have bleeding problems. They also do not produce hemoglobin or red cells (that carry oxygen), so they may become anemic and feel tired.

The word "acute" means sudden or rapid in onset. Acute leukemia can occur in a short period of days or weeks. Chromosome (DNA) abnormalities (extra chromosomes and structural changes in the chromosome material) are present in the majority of patients with ALL.

This content was last reviewed August 15, 2010 by Dr. Reshma L. Mahtani.
Latest Cancer News
REFILE: Komen charity under microscope for funding, science

February 8, 2012 — NEW YORK (Reuters) - The Susan G. Komen for the Cure charity defines its mission as finding a cure for breast cancer. In recent years, however, it has cut by nearly half the proportion of fund-raising dollars it spends on grants to scientists working to understand the causes and develop effective new treatments for the disease.

US FDA panel votes against wider use of Amgen drug

February 8, 2012 — WASHINGTON (Reuters) - An advisory panel on Wednesday recommended that U.S. health regulators reject the use of Amgen Inc's drug Xgeva to delay the spread of prostate cancer to the bone, dimming the chance of a wider use for one of the company's key growth drivers.

US consumers want tougher probe of engineered salmon

February 8, 2012 — WASHINGTON (Reuters) - Three U.S. consumer groups petitioned the Food and Drug Administration on Tuesday to subject a new genetically engineered salmon to a more rigorous review process than is now in place before the fish can be approved as safe to eat.

Select news items provided by Reuters Health